Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer

Citation
M. Matsumoto et al., Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer, JPN J CANC, 92(1), 2001, pp. 51-58
Citations number
35
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
JAPANESE JOURNAL OF CANCER RESEARCH
ISSN journal
0910-5050 → ACNP
Volume
92
Issue
1
Year of publication
2001
Pages
51 - 58
Database
ISI
SICI code
0910-5050(200101)92:1<51:PIVAEO>2.0.ZU;2-W
Abstract
The antitumor efficacy of the combination of nedaplatin (NDP) with gemcitab ine (GEM) was evaluated. We also compared the antitumor activity of NDP plu s GEM with that of cisplatin (CDDP) plus GEM or carboplatin (CBDCA) plus GE M. Ma44, which is a human lung cancer sensitive to GEM, and NCI-H460, which is a human lung cancer refractory to GEM, were used in this study. GEM was injected i.v. once followed by i.v. injection of NDP at an interval of app roximately 30 min into tumor-bearing athymic mice. GEM was administered aga in 3 or 4 days thereafter. Combined dosing of NDP with GEM resulted in syne rgistically enhanced inhibition of tumor growth in the Ma44 tumor model. ND P plus GEM was also effective against Ma44 cells when given late in the the rapy, a model for advanced disease. Potent augmentation of growth inhibitio n by NDP with GEM was also found with the NCI-H460 tumor model. The combina tion effect of NDP plus GEM appeared to be superior to that of CDDP plus GE M or CBDCA plus GEM in both tumor models. Toxicity in terms of blood cell n umbers was not enhanced by the combination of NDP with GEM. These results s uggest the effectiveness of combination of NDP with GEM for clinical therap y.